Chimeric antigen receptor (CAR) T cells (CAR-T) targeting CD19 have revolutionized the treatment for B cell lymphomas; however, only single cases of patients with CNS manifestations successfully treated with CD19 CAR-T have been reported [5]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.